US Fecal Microbiota Transplant Market, Drug Price and Clinical Trials Outlook 2028

  • No. of Pages: 100
  • Publish Date: September-2023
  • Category: Pharmaceutical and Healthcare
Electronic Access - Single User License
CD-ROM Mail Delivery
Hard Copy Mail Delivery
Electronic Access - Multi-User License

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

US Fecal Microbiota Transplant Market, Drug Price and Clinical Trials Outlook 2028 Report Highlights:


  • Research Methodology
  • US Fecal Microbiota Transplant Market Opportunity: > US$ 200 Million
  • Number of Approved Drugs: 2
  • Approved Drugs, Dosage, Pricing and Reimbursement Insight
  • Insight On US Fecal Microbiota Transplant Drugs In Clinical Trials: > 35 Drugs
  • US Fecal Microbiota Transplant Drugs Clinical Trials Insight By Company, indication and Phase
  • Competitive Landscape


The Fecal Microbiota Transplantation (FMT) market in the US is undergoing a remarkable transition, combining the realms of therapeutic innovation and commercial opportunity. Moreover, recent developments in microbiota research and increasing comprehension of the various bodily functions that gut can influence has propelled the US Fecal Microbiota Transplantation market to increasing heights. As a result, it becomes critical to traverse this rapidly developing market with a key eye. The US Fecal Microbiota Transplantation market is fairly diverse with researchers constantly making different clinical breakthroughs and the resulting economic opportunities. The dynamic convergence of healthcare and commerce with the US Fecal Microbiota Transplantation market has been quite beneficial for the market, from pioneering clinical applications to key companies driving market growth.


Fecal Microbiota Transplantation, once seen as an unconventional and detestable method, is now becoming more well-known for its success in treating a variety of gastrointestinal conditions. The primary application of FMT is still in clostridium difficile (C. difficile or C. diff) infection. Fecal Microbiota Transplantation is frequently regarded as the last choice for patients who do not respond to antibiotics because of the amazing success rates in C. difficile infection. However, research is broadening the use of FMT in diseases like autoimmune diseases, inflammatory diseases, and viral infections among others. Lately, FMT is also finding use in the management of adverse events caused as a result of different cancer treatments, majorly immune checkpoint inhibitors, which can give rise to colitis and diarrhea.


Moreover, the FDA has also begun the process of regulating Fecal Microbiota Transplantation as a biologic medicine. Earlier, though Fecal Microbiota Transplantation was recommended by the FDA for preventing recurrence of C. difficile infection, providers were not required to meet the IND standards. However, in a new announcement made in November 2022, the FDA has recommended FMT developers to meet the FDA’s regulatory standards. This regulatory system assures that the fecal material used in transplantation is safe and of high quality. This governmental scrutiny has given the Fecal Microbiota Transplantation procedure legitimacy and increased investor confidence in this developing field.


The Fecal Microbiota Transplantation market in the US has grown rapidly in recent years with rates exceeding what was envisioned. This can be attributed to growing knowledge among healthcare professionals and consumers in the region, which has increased trust FMT and hence its uptake. Moreover, the increase in recurrent C. difficile infection has also contributed to the increasing prescription of Fecal Microbiota Transplantation. A further expansion of Fecal Microbiota Transplantation in other indications is also expected to increase the popularity of the therapy as a dependable treatment approach for illnesses spanning different disease classes.


Several companies, notable Rebiotix (a subsidiary of Ferring Therapeutics), Seres Therapeutics, Finch Therapeutics, and OpenBiome, have emerged as important players in the Fecal Microbiota Transplantation market. The FDA approved the Fecal Microbiota Transplantation products Rebyota and Vowst in November 2022 and April 2023, which were developed by Rebiotix and Seres Therapeutics respectively, increasing their status in the US as well as the global FMT market.


Collaborations and partnerships are becoming more widespread as these organizations strive to capitalize on one another’s skills in order to create and commercialize Fecal Microbiota Transplantation based products. For instance, Finch Therapeutics is collaborating with the Arizona State University and the University of Minnesota to conduct clinical trials for an investigational microbiota transfer therapy (MTT), which combines fecal microbiota transplant with pre-treatment with the antibiotic vancomycin to kill pathogenic bacteria, in pediatric patients with both Autism Spectrum Disorder and gastrointestinal problems.


As a result, the Fecal Microbiota Transplantation market has grown from a specialized technique to a vibrant and attractive industry within the US pharmaceutical industry. Despite its expansion, the FMT market still faces obstacles like procedural uniformity, problems with funding, and consumer worries about donor safety and screening. Therefore, to support market growth, addressing these issues will be needed. The US Fecal Microbiota Transplantation market is in a stage of transition where clinical developments, regulatory policy chances and developing marketing trends are boosting its expansion and rise as a prominent industry in the US.

Need custom market research solution? We can help you with that too.